Abstract

The acid–base properties and the Cu(II) binding processes of methotrexate (MTX) were characterized by selected spectroscopic techniques and potentiometric measurements. The pH titration data showed that MTX behaves as a triprotic ligand. The deprotonation constants were determined for α-COOH and γ-COOH groups and (N1)H+ from the pteridine ring. Taking all the obtained results into consideration, a coordination pattern was proposed. The DNA-cleaving activity and reactive oxygen species (ROS) generation were investigated for both MTX and the Cu(II)–MTX system. The complex displayed a promising nuclease activity toward plasmid DNA in the presence of hydrogen peroxide. Interestingly, the induction of ROS, such as hydroxyl radicals, superoxide anions or singlet oxygen, was excluded and a different mechanism of DNA degradation was proposed. As MTX is now commonly used in anticancer therapy i.e. against lung cancer, basic cell-based studies were carried out to establish if its Cu(II) complex exhibits higher cytotoxic properties than the ligand alone. Activities of both compounds were also tested against colon carcinoma. Moreover, the determined values of IC50 were confronted with the cytotoxic activity of cisplatin.Electronic supplementary materialThe online version of this article (doi:10.1007/s00044-014-1074-1) contains supplementary material, which is available to authorized users.

Highlights

  • Methotrexate (MTX, (2S)-2-[(4-{[(2,4-diaminopteridin-6yl)methyl](methyl)amino}benzoyl)amino]pentanedioic acid) is a folic acid antagonist and it has a therapeutic effect on many types of cancer cells

  • The responsibility for the plasmid degradation processes may be attributed to the copper-oxene or coppercoordinated hydroxyl radical

  • Investigations of the anticancer activity showed that the complex generally displays higher cytotoxicity in vitro than the ligand and metal ion separately and is more selective against A459 cell line

Read more

Summary

Introduction

Methotrexate (MTX, (2S)-2-[(4-{[(2,4-diaminopteridin-6yl)methyl](methyl)amino}benzoyl)amino]pentanedioic acid) is a folic acid antagonist and it has a therapeutic effect on many types of cancer cells. It is currently widely used as a major chemotherapeutic agent for human malignancies, such as acute lymphoblastic leukemia, lymphoma, osteosarcoma, and breast, lung, head, and neck cancers (Yoon et al, 2010). Polyglutamates block the synthesis of purines and pyrimidines by inhibiting dihydrofolate reductase and several other folate-dependent enzymes. This blocking results in the disruption of DNA biosynthesis and is the basis of MTX chemotherapeutic action (Chibber et al, 2012). Tumor cells require about tenfold higher concentration of thymidine triphospate than healthy cells, and they are more sensitive to the effects of antifolates (Navarro-Peran et al, 2005)

Objectives
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call